BioSpace News Archive

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that it will release financial results for its 2023 second quarter on Thursday, August 10, 2023 before the open of the U.S. financial markets.

Rockwell Medical, Inc. announced that it will release its financial and operational results for the second quarter ended June 30, 2023 on Monday, August 14, 2023.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today reported results from an open-label proof-of-concept clinical study for ld IL-2 in patients with AD.

Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development of cirrhosis and liver cancer.

CytomX Therapeutics, Inc. today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO).

Avertix Medical, Inc. announced that Professor Ian Meredith AM, has agreed to join the Company’s Board of Directors following the closing of the Company’s previously announced business combination with BIOS Acquisition Corporation, a special purpose acquisition company.

Assembly Biosciences, Inc. today announced data from development candidate ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor targeting high-recurrence genital herpes, featured in one oral and one poster presentation at the 47th Annual International Herpesvirus Workshop in Missoula, Montana, taking place July 15-19, 2023.

NKGen Biotech Inc. (NKGen) today announced the presentation of a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands.

Vaxxinity, Inc. today announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays.

Travere Therapeutics, Inc. (NASDAQ: TVTX) and Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that they have entered into a definitive agreement for the sale of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings.